Proteomics International - Biosimilars, Biomarkers & Therapeutics

proteomics.com.au

Founded 2001 Listed on ASX April 2015 - Proteomics International Laboratories Ltd (PILL, ASX: PIQ) Proteomics International is a medical technology company focused on proteomics – the industrial-scale study of the structure and function of proteins. Proteomics International has over 16 years of experience in providing specialist analytical services on a fee-for-service basis . The strength of the company’s research expertise in finding new diagnostic protein biomarkers has also resulted in a ground-breaking predictive test for diabetic kidney disease – PromarkerD.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Diagnostics

EXOTHERA ANNOUNCES INDUSTRIAL SCALE AAV MANUFACTURING COLLABORATION WITH LOGICBIO THERAPEUTICS AND POLYPLUS

Exothera | June 15, 2022

news image

Exothera SA today announced a collaboration with LogicBio® Therapeutics and Polyplus-transfection® SA. for the development of a highly scalable AAV manufacturing platform with a capacity from 200 L to 2,000 L. Adeno-associated viruses (AAV) are non-enveloped, non-pathogenic viruses largely used as drug delivery vectors for biotherapeutics, like gene therapies and vaccines. Although the application of AAV is spreading rapidly, the industry is struggling to find cost-effecti...

Read More

Research

VIRIOS THERAPEUTICS TO PRESENT AT THE VIRTUAL H.C. WAINWRIGHT BIOCONNECT CONFERENCE

Virios Therapeutics, Inc. | January 05, 2022

news image

Virios Therapeutics, Inc. a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced that Greg Duncan, Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright BioConnect Conference, which is taking place virtually January 10 - 13, 2022. The presentation will focus on the role of activated viruses triggering a wide range of conditions, includi...

Read More

MedTech

NEUMORA THERAPEUTICS ANNOUNCES $112 MILLION SERIES B FINANCING

Neumora | October 12, 2022

news image

Neumora Therapeutics, Inc. a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience, today announced the close of a $112 million Series B financing. The Series B syndicate includes both new and existing investors, such as Abu Dhabi Growth Fund Altitude Life Science Ventures, Amgen, ARCH Venture Partners, Exor Ventures, F-Prime Capital, Invus, Mubadala Capital, Newpath Partners, Polaris Partners and other und...

Read More

DNA SEQUENCING PRODUCTS MARKET DEMAND, RECENT TRENDS AND DEVELOPMENTS ANALYSIS 2025

Express Journal | April 13, 2020

news image

As per the report, the DNA Sequencing Products market is predicted to gain significant returns while registering a lucrative annual growth rate during the foreseen time period. Exposing an enthralling outline of this DNA Sequencing Products industry, the report provides details about the complete valuation of the market, growth opportunities in the business verticals along with a detailed classification of the DNA Sequencing Products market. DNA Sequencing Products Market report is an extensive ...

Read More
news image

Diagnostics

EXOTHERA ANNOUNCES INDUSTRIAL SCALE AAV MANUFACTURING COLLABORATION WITH LOGICBIO THERAPEUTICS AND POLYPLUS

Exothera | June 15, 2022

Exothera SA today announced a collaboration with LogicBio® Therapeutics and Polyplus-transfection® SA. for the development of a highly scalable AAV manufacturing platform with a capacity from 200 L to 2,000 L. Adeno-associated viruses (AAV) are non-enveloped, non-pathogenic viruses largely used as drug delivery vectors for biotherapeutics, like gene therapies and vaccines. Although the application of AAV is spreading rapidly, the industry is struggling to find cost-effecti...

Read More
news image

Research

VIRIOS THERAPEUTICS TO PRESENT AT THE VIRTUAL H.C. WAINWRIGHT BIOCONNECT CONFERENCE

Virios Therapeutics, Inc. | January 05, 2022

Virios Therapeutics, Inc. a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced that Greg Duncan, Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright BioConnect Conference, which is taking place virtually January 10 - 13, 2022. The presentation will focus on the role of activated viruses triggering a wide range of conditions, includi...

Read More
news image

MedTech

NEUMORA THERAPEUTICS ANNOUNCES $112 MILLION SERIES B FINANCING

Neumora | October 12, 2022

Neumora Therapeutics, Inc. a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience, today announced the close of a $112 million Series B financing. The Series B syndicate includes both new and existing investors, such as Abu Dhabi Growth Fund Altitude Life Science Ventures, Amgen, ARCH Venture Partners, Exor Ventures, F-Prime Capital, Invus, Mubadala Capital, Newpath Partners, Polaris Partners and other und...

Read More
news image

DNA SEQUENCING PRODUCTS MARKET DEMAND, RECENT TRENDS AND DEVELOPMENTS ANALYSIS 2025

Express Journal | April 13, 2020

As per the report, the DNA Sequencing Products market is predicted to gain significant returns while registering a lucrative annual growth rate during the foreseen time period. Exposing an enthralling outline of this DNA Sequencing Products industry, the report provides details about the complete valuation of the market, growth opportunities in the business verticals along with a detailed classification of the DNA Sequencing Products market. DNA Sequencing Products Market report is an extensive ...

Read More

Resources

resource image

Cell and Gene Therapy, Industrial Impact

Improve Your Gene-Editing Success With CRISPR-SNIPER Technology

Whitepaper

resource image

Cell and Gene Therapy, Industrial Impact

HIGH THROUGHPUT AAV VIRAL TITERING USING NANOPLATE-BASED DIGITAL PCR

Whitepaper

resource image

Cell and Gene Therapy, Industrial Impact

Eliminate Noisy Oxygen Measurements in Bioreactors

Whitepaper

resource image

Cell and Gene Therapy, Industrial Impact

Improve Your Gene-Editing Success With CRISPR-SNIPER Technology

Whitepaper

resource image

Cell and Gene Therapy, Industrial Impact

HIGH THROUGHPUT AAV VIRAL TITERING USING NANOPLATE-BASED DIGITAL PCR

Whitepaper

resource image

Cell and Gene Therapy, Industrial Impact

Eliminate Noisy Oxygen Measurements in Bioreactors

Whitepaper

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us